Scalper1 News
Valeant Pharmaceuticals (VRX) on Monday announced a deal to acquire PreCision Dermatology for $475 million in cash, sending Valeant stock lower. The deal is expected to close in the first half of the year, and Valeant will pay an extra $25 million if PreCision hits a “sales-based milestone,” Valeant said in a press release. Shares of Valeant, one of Canada’s biggest drugmakers, dipped about 2% on the stock market today. Cumberland, R.I.-based Scalper1 News
Scalper1 News